Boswellic Acids Reduce Systemic Inflammation in COVID-19 Patients Through NF-kB Pathway Modulation
Nikhil Prasad Fact checked by:Thailand Medical News Team Mar 03, 2025 10 hours, 32 minutes ago
Medical News: Promising Natural Approach to COVID-19 Inflammation Management
A new study has highlighted the potential of boswellic acids in reducing inflammation in patients with moderate COVID-19. The study investigated how a specific formulation of boswellic acids, known as Inflawell syrup, influences inflammatory markers in the body. The findings suggest that the compound can significantly reduce key inflammatory cytokines, potentially offering a new complementary treatment approach for COVID-19 patients experiencing immune system overactivity.
Boswellic Acids from the Frankincense Tree Can Reduce Systemic Inflammation in COVID-19
Patients Through NF-kB Pathway Modulation
COVID-19 has been linked to severe immune system dysregulation, which can lead to excessive inflammation and complications. This
Medical News report examines how boswellic acids, a group of phytochemical compounds derived from the Boswellia tree (Frankincense tree), may provide relief by modulating inflammatory pathways in the body. Researchers focused on the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, a key regulator of immune response and inflammation, to determine how Inflawell syrup influences cytokine levels in COVID-19 patients.
Study Design and Key Findings
The study involved patients diagnosed with mild to moderate COVID-19. Participants were divided into two groups: one receiving Inflawell syrup containing boswellic acids and the other receiving a placebo. Treatment lasted for 14 days, during which researchers monitored changes in inflammation-related biomarkers. Blood samples were collected from all participants at the start of the study and again after two weeks.
Results showed a significant reduction in several key inflammatory cytokines in patients treated with Inflawell. Specifically, levels of interleukin-1 alpha (IL-1α), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) decreased notably in the Inflawell group compared to the placebo group. The reductions were statistically significant, with p-values confirming meaningful differences in inflammation levels. For example:
-IL-1α levels dropped significantly (p < 0.009)
-IL-8 showed a notable decline (p < 0.04)
-TNF-α was substantially reduced (p < 0.0001)
-MCP-1 experienced a measurable decrease (p < 0.007)
In addition to cytokine reduction, the study examined NF-κB pathway components to determine how boswellic acids influence inflammatory signaling.
The data revealed that:
-Levels of NF-κB p65 mRNA were significantly lower (p < 0.002)
-Phosphorylated IκB protein (phospho-IκB), a molecule involved in NF-κB activation, was reduced (p < 0.02)
-Overall IκB protein levels increased (p < 0.01), suggesting less inflammation-related degrad
ation of this molecule
While the study also assessed the expression of tumor necrosis factor receptors TNFR1 and TNFR2, no statistically significant changes were observed between the Inflawell and placebo groups.
Implications and Future Research
The findings indicate that boswellic acids may help regulate the immune response in COVID-19 by reducing pro-inflammatory cytokines and suppressing NF-κB pathway activation. This could be especially beneficial for patients experiencing excessive inflammation, a condition known as a cytokine storm, which has been linked to severe COVID-19 complications.
Since Inflawell demonstrated promising results in lowering inflammation without apparent adverse effects, researchers suggest further studies to confirm its efficacy on a larger scale. Additional research could also explore whether boswellic acids might benefit other inflammatory conditions beyond COVID-19, such as autoimmune diseases and chronic inflammatory disorders.
Conclusion
This study provides valuable insight into how natural compounds like boswellic acids can modulate immune responses and help manage COVID-19 inflammation. The results demonstrate that Inflawell syrup significantly reduces inflammatory cytokines and suppresses the NF-κB signaling pathway, indicating a potential role as a complementary treatment for COVID-19 patients. While the findings are promising, further clinical trials are needed to determine the long-term benefits and optimal usage of boswellic acid-based treatments. If additional studies confirm these effects, boswellic acids could become an important tool in managing immune system overactivity in infectious diseases and beyond.
The study findings were published in the peer-reviewed Journal of Dietary Supplements.
https://www.tandfonline.com/doi/full/10.1080/19390211.2025.2468484
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/key-biomarkers-of-inflammation-and-tissue-damage-in-covid-19-patients
https://www.thailandmedical.news/news/cells-that-survive-acute-sars-cov-2-infection-play-a-role-in-lung-inflammation-and-recovery
https://www.thailandmedical.news/news/sars-cov-2-also-targets-the-nervous-system-of-eyes-causing-ocular-neuroinflammation
https://www.thailandmedical.news/articles/coronavirus
https://www.thailandmedical.news/pages/thailand_doctors_listings
Share
Tweet
Share
